Genentech, Inc.

Seattle Genetics, Inc.

Genetech, Inc.

Nerviano Medical Sciences S.r.l.

F. Hoffmann-la Roche Ag

Seagen Inc.

Spirogen Sarl

Susan D Spencer

Paul Polakis

Zemin Zhang

Thomas J Wu

Gretchen Frantz

Victoria Smith

Kenneth J Hillan

Mark X Sliwkowski

P Mickey Williams

Allen J Ebens

Heidi S Phillips

Peter Senter

Svetlana Doronina

Brian E Toki

Toni Beth Kline

Hartmut Koeppen

Ruihuan Chen

Belinda Cairns

Mark S Dennis

John A Flygare

Andrew G Polson

Yin Sheng Zhang

Michele Caruso

Italo Beria

Matteo Salsa

Vittoria Lupi

Barbara Valsasina

Suzanna J Scales

Rita Perego

Svetlana O Doronina

Ralph H Schwall

Robert L Cohen

Frederic S Jacobson

Patrick Dowd

Philip Wilson Howard

Anan Chuntharapai

Luke Masterson

Chie Sakanaka

Peter D Senter

Helga E Raab

Heidi Phillips

Chae Janeka Reed

Arnaud Tiberghien

Yin Zhang

Thomas D Wu

Mickey P Williams

Kartmut Koeppen

The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.

Anti-mesothelin antibodies and immunoconjugates

The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.

Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof

The present invention relates to antibody-drug conjugate compounds of Formula I:Ab-(L-D)&#x2003;&#x2003;Iwhere one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

Antibody-drug conjugates and methods

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. TAT113 polypeptides comprising the amino acid sequence of SEQ ID NO: 2 are disclosed. Antibodies that bind TAT113 polypeptides, including monoclonal, chimeric, humanized, single chain, and other antibodies, and fragments thereof, are disclosed. Methods of identifying antibodies that bind epitopes bound by such antibodies, including the antibodies produced by hybridoma cell lines disclosed in the application, are provided, wherein the ability of one antibody to block the binding of another antibody to a TAT113 polypeptide indicates that one antibody binds to an epitope bound by the other antibody. Methods of diagnosing the presence of a tumor in a mammal using such antibodies are disclosed, wherein detection of the formation of a complex between an antibody and a protein in a test sample is indicative of the presence of a tumor in said mammal. Methods of inhibiting the growth of a cancer cell that expresses a protein comprising the amino acid sequence of SEQ ID NO: 2, are disclosed, where the binding of the antibody to the protein inhibits the growth of the cell. Methods of inhibiting the growth of a cancer cell include methods wherein the antibody binds to the epitope bound by an antibody produced by a disclosed hybridoma cell line.

Compositions and methods for the diagnosis and treatment of tumor

The present invention relates to antibody-drug conjugate compounds of Formula I:Ab-(L-D)&#x2003;&#x2003;I

Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

Monomethylvaline compounds capable of conjugation to ligands

Growing community of inventors

Tiburon, CA, United States of America

Susan D Spencer